

Special Issue

Ophthalmic Adverse Events following SARS-CoV-2 Vaccination

Message from the Guest Editor

In December 2020, the largest global vaccination efforts were launched to limit the spread and clinical severity of SARS-CoV-2. Although the vaccines have been reported to be highly efficacious in limiting the impact of SARS-CoV-2, their swift development and emergency use authorizations limited the short and long-term evaluation of rare adverse events in real-world settings. Over the past 20 months, several reports and studies have highlighted the adverse events (such as myocarditis, Guillain–Barré syndrome, etc.) following the administration of these vaccines. In this special edition, we are compiling case reports, series, review articles and studies focused on ophthalmic adverse events following SARS-CoV-2 vaccinations. The submissions may include:

- Case of rare ophthalmic adverse events following vaccination
- Studies reporting risk of ophthalmic adverse events following vaccine
- Analysis of global databases reporting vaccine-associated ophthalmic adverse events
- Review articles evaluating published literature on ocular adverse events with special emphasis on underlying potential mechanisms.

Guest Editor

Dr. Rohan Bir Singh

1. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
2. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
3. Discipline of Ophthalmology and Visual Sciences, Faculty of Health and Medical Sciences, Adelaide Medical School, University of Adelaide, Adelaide, Australia

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/133575

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).